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Abstract 
Objective: Estimate the mortality impact of delay in antiretroviral therapy (ART) initiation from the time 
of entry-into-care. 
Design: A state-transition Markov process model.  This technique allows for assessing mortality before 
and after ART initiation associated with delays in ART initiation among a general population of ART 
eligible patients without conducting a randomized trial.  
Methods: We used patient-level data from three South African cohorts to determine transition 
probabilities for pre-ART CD4 count changes and pre-ART and on-ART mortality.  For each parameter we 
generated probabilities and distributions for Monte Carlo simulations with one week cycles to estimate 
mortality 52 weeks from clinic entry. 
Results: We estimated an increase in mortality from 11.0% to 14.7% (relative increase of 34%) with a 10 
week delay in ART for patients entering care with our pre-ART cohort CD4 distribution.  When we 
examined low CD4 ranges, the relative increase in mortality delays remained similar; however, the 
absolute increase in mortality rose.  For example, among patients entering with CD4 count 50-99 
cells/mm
3
, 12 month mortality increased from 13.3% with no delay compared to 17.0% with a 10 week 
delay and 22.9% with a 6 month delay.  
Conclusions: Delays in ART initiation, common in routine HIV programs, can lead to important increases 
in mortality.  Prompt ART initiation for patients entering clinical care and eligible for ART, especially 
those with lower CD4 counts, could be a relatively low cost approach with a potential marked impact on 
mortality. 
Key words: ART delay; Africa; CD4 count; mortality; state-transition model 
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Introduction 
Use of combination antiretroviral therapy (ART) dramatically reduces mortality among people living with 
HIV 
1;2
 with maximal benefit when ART is started at higher CD4 counts.
3-5
  However, in many sub-Saharan 
African clinical settings, patients meeting local ART initiation guidelines experience delays of several 
weeks to several months in initiating treatment.
6-9
  These delays may occur as a result of health system, 
provider, and patient-level factors.  For example, ART agent shortages and ART waiting lists are health-
system factors leading to delay.
10-13
  Pre-ART counseling sessions and investigations for TB and other 
opportunistic diseases are clinic or provider-level factors that may lead to delay, while failure to return 
for timely clinic visits or declining ART due to fears of ART side effects are patient-level factors.
8;14-17
  
Hesitation by a patient to accept ART may reflect a combination of patient-level and provider-level 
factors if the patient has not received an accurate and consistent message on the value of ART.  
Several recent clinical trials have demonstrated reduced survival with delays in ART initiation in patients 
with an opportunistic illness or tuberculosis (TB).
18-22
  These trials highlight the benefit of prompt ART 
initiation in HIV infected patients with lower CD4 counts (<50 cells/mm
3
) and raise a question regarding 
whether ART delay causes a similar increase in mortality among ART-eligible people who do not present 
with opportunistic disease.  If so, then accelerating ART initiation may be a key priority for reducing HIV-
associated mortality.  To address this question, using patient-level mortality and CD4 count data from 
three cohorts in South Africa, we developed a Markov state-transition model to simulate one-year 
mortality from time from entry into HIV care under different scenarios for time to ART initiation. 
Methods 
Model Structure  
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We constructed a Markov state-transition model to simulate mortality while allowing for variation in 
timing of ART initiation (0 to 52 weeks after clinic entry) and variation in CD4 count state at clinic entry.  
By simulating thousands of patients, this model can provide an estimate of mortality based on ART delay 
and CD4 count state at clinic entry.  The model allows for transitions between CD4 count states prior to 
ART initiation and transition between alive and dead, prior to ART initiation and on-ART (Figure 1).   
Patient-level data from three cohorts were used to calculate parameters and parameter variance for the 
model.  These cohorts were (i) a study of isoniazid preventive therapy among mine workers with HIV 
conducted prior to the availability of ART,
23
 (ii) data from a large cohort of patients who were provided 
free HIV care services through a network of community general practitioner HIV providers,
24
 and (iii) 
data from a centrally managed ART program in multiple workplace and community clinics.
25
  Isoniazid 
preventive study patient-level data were used to calculate CD4 count state transition probabilities, the 
community general practitioner cohort (the pre-ART cohort) was used to calculate pre-ART mortality, 
and the ART program cohort (the ART cohort) was used to calculate on-ART mortality.  In developing 
transition probabilities for the state-transition model, we described uncertainty in the CD4 count state 
transition probabilities using a beta distribution, based on the mean and standard deviation.  We also 
used a beta distribution to describe pre-ART mortality uncertainty generated from the means and 
standard errors from the primary data.  For on-ART mortality, we generated mortality uncertainty 
distributions following a Normal distribution with a mean centered at the estimated mortality 
probability and standard deviation of 0.2 (greater detail on the model construction and transition 
probabilities are provided in a Technical Appendix available as Supplemental Digital Content, 
http://links.lww.com/QAI/A393).  
We used probabilistic modeling of CD4 state transitions and mortality by sampling from transition 
distributions in a Monte Carlo micro-simulation (Figure 1). For the purposes of estimating the “whole 
AC
CE
PT
ED
Copyright   Lippincott Williams & Wilkins. All rights reserved.
7 
cohort” impact of reducing time to ART initiation, we evaluated mortality in a hypothetical cohort of 
1000 patients whose CD4 distribution at clinic entry was set to be the same as our patient level data in 
our pre-ART cohort.  We further analyzed a sub-group of the whole cohort, limiting to patients entering 
care with CD4 counts <150 cells/mm
3
.  In order to allow for comparisons of impact of ART delay by CD4 
count at clinic entry we also separately modeled outcomes for each CD4 count state. 
We developed the state-transition model using TreeAge Pro 2011 software (TreeAge Software Inc., 
Williamstown, MA, USA).  Monte Carlo micro-simulation of 10,000 cohorts each with 1000 patients was 
used to estimate mortality probabilities and 95% uncertainty ranges.  We performed the following 
uncertainty analyses: (1) excluding patients with TB disease diagnosed at the time of entry into pre-ART 
care and (2) separately adjusting CD4 state transition, pre-ART mortality, and on-ART mortality by a 
relative increase or decrease of 25% while repeating the whole cohort analysis for 0, 10 and 26 week 
delays in ART initiation. 
Data analysis used to populate model 
For parameter estimation from each of the three cohorts (CD4 transition, pre-ART, and on-ART) we 
included all adults (age ≥18 years) who were ART naïve and had WHO clinical stage I, II, or III conditions 
at cohort entry.  We excluded patients with WHO clinical stage IV conditions as disease specific 
management strategies may influence both timing of ART initiation and mortality.  For the pre-ART and 
on-ART cohorts, we maximized ascertainment of deaths using clinic reports and linkage of national civil 
identification numbers to the South African Department of Home Affairs vital status registry.  This 
linkage provided the date of death for deceased patients among the 65% (pre-ART cohort) to 80% (ART 
cohort) of patients with valid national ID numbers.  Linkage was performed one month after our cohort 
closure date.  We estimated mortality among those lost to follow-up but without identification numbers 
through inverse probability weighting.
26;27
  To calculate CD4 transitions pre-ART, we stratified all 
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longitudinal CD4 count values into one of 9 states: <25, 25-49, 50-99, 100-149, 150-199, 200-249, 250-
299, 300-349, and ≥350 cells/mm
3
.  For each of the nine CD4 states, we calculated the Nelson-Aalen 
hazards of transition to another CD4 state and expressed these as one-week probabilities.  To determine 
pre-ART mortality, we used survival analysis with cohort entry defined as the first CD4 count.  We used 
time of first CD4 count as time of clinic entry because CD4 count enumeration generally occurs at this 
time in the South African context.  Patients exited at the time of death or were censored at ART 
initiation; because we could ascertain vital status through national registry linkage, we did not censor 
based on loss from care.  Mortality hazard, stratified by CD4 count, was relatively constant over follow-
up time.  Thus we converted the six-month Nelson-Aalen survival probability into a one-week mortality 
probability.  We calculated mortality hazard in the on-ART cohort using Nelson-Aalen hazards based on 
the CD4 count state at ART initiation and time on ART.  Because the decline in mortality, by time on ART, 
approximated the initial slope of an exponential decline, we used an exponential distribution to 
estimate weekly mortality probabilities by duration on ART.   
Results 
Data analysis to populate model: 
The CD4 transition cohort had 1,413 ART naïve individuals with a median of 3 (interquartile range; IQR: 
2, 4) CD4 assays and median interval between measurements of 196 (IQR: 175, 308) days.  The pre-ART 
cohort consisted of 31,017 individuals contributing 41,724 years of observation.  The median CD4 count 
at care entry was 216 (IQR: 96-376) with none of the 9 CD4 count strata containing less than 9% or more 
than 15% of the population.  Among those meeting an ART eligibility threshold of <350 cells/mm
3
, the 
median CD4 count was 143 cells/mm
3
 and 56% were men. The on-ART cohort consisted of 23,940 
individuals contributing 61,374 person years of observation.  The median CD4 at ART initiation was 147 
cells/mm
3
 (IQR: 66, 228) and 58% were men.   
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Markov state-transition model – CD4 count changes 
We estimated that patients with CD4 counts of 350 and 75 cells/mm
3
 would have CD4 cell declines of 48 
and 71 cells/mm
3
/year, respectively.  Using the entry CD4 distribution of the pre-ART cohort, we 
estimated a 10% pre-ART mortality 6 months from clinic entry without ART initiation.  Among the 
survivors at 6 months, 52% remained in the CD4 state in which they entered care, 7.8% increased by one 
or more states, 22% decreased by one state, and 6.0% decreased by two or more states.  During the 
subsequent 26 weeks of ART, 9% of the pre-ART survivors died for a total 52 week mortality of 19%.  
Markov state-transition model - Mortality by delay in ART initiation  
Using a hypothetical whole cohort with the same CD4 count distribution as seen in our pre-ART cohort, 
11.1% of the population (95% CI: 7.2-15%) were projected to die within 52 weeks, if ART was started 
immediately on clinic entry.  Deaths increased to 13.2% (95% CI: 9.5-17%) with a 6 week delay, 14.7% 
(95% CI: 11-18%) with a 10 week delay, 19.6% (95% CI: 16-23%) with a 26 week delay, and 24% (95% CI: 
20-29%) with a 52 week delay (Table 1).  Thus, as compared with immediate ART initiation, delaying ART 
initiation by 10 weeks resulted in 37 additional deaths (34% increase in one-year mortality) and delaying 
by 52 weeks resulted in 130 additional deaths (118% increase), per 1,000 patients.   
Limiting the simulation to patients entering with CD4 <150 cells/mm
3
, we observed an increase in 
mortality from 160 deaths per 1000 patients with no delay, to 210 deaths with a 10 week delay (31% 
increase) and 340 deaths (112% increase) with a 52 week delay.   
The effect of ART delay on mortality within specific CD4 count states at clinic entry is presented in Table 
1 and graphically presented in Figure 2.  The effect of a 10 week delay among patients with a CD4 count 
of 50-99 cells/mm
3
 was an increase of 37 deaths in a cohort of 1000 patients (31% increase).  A 26 week 
delay was associated with an increase of 96 deaths (77% increase).   
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Excluding patients with TB at clinic entry (5.6% of all patients) gave similar results (results not shown).  
To assess the impact of uncertainty on state change probabilities, we performed serial one-way analyses 
with a relative 25% increase or decrease in probability for each parameter for CD4 state transitions, pre-
ART mortality, and on-ART mortality (Figure 3).  The ranges for the 52-week mortality for 0, 10, and 26 
week delays in ART initiation after these one-way uncertainty analyses all fell within our simulated 
uncertainty ranges (Table 1).  
Discussion 
Using data from South African cohorts we modeled a relative 34% increase in 12 month mortality 
attributable to a 10 week delay in ART initiation.  A 10 week delay is consistent with the range reported 
in the literature of 9 to 125 days 
8;10;28-32
 as well as our experience in a hospital-based ART program.
33
  
Notably, the absolute increase in mortality was highest with lower CD4 count states.  For example, a 10-
week delay in ART initiation would be expected to result in 15 excess deaths per 1000 patients with CD4 
counts at clinic entry between 200-249 cells/mm
3
, compared to 37 excess deaths among patients 
entering with CD4 counts between 50-99 cells/mm
3
.  Thus potential gain in survival, if a 10 week delay in 
ART initiation could be eliminated, is only slightly less than the estimated 40% relative reduction in 
mortality during the first year of ART through universal use of cotrimoxazole prophylaxis.
34-36
 
While there are no empirical studies of ART delay and mortality from clinic entry and after ART initiation 
in an unselected population, we can compare estimates from each of our parameters with prior 
parameter specific reports.  Our estimates of pre-ART mortality are similar to prior reports from Africa 
(Table 2).
37-39
  In this regard, the similarity of our estimates with observational data supports the validity 
of the pre-ART parameters of our model.  In contrast, our parameter-based estimates of on-ART 
mortality are somewhat higher than previously reported (Table 2) 
40-43
.  This discrepancy in on-ART 
mortality may be a result of deriving our parameters from data linked to a robust national vital status 
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registry leading to greater ascertainment of deaths.  Such registers are not widely available in sub-
Saharan Africa outside of South Africa.  Failure to completely ascertain deaths among patients lost to 
follow-up can markedly reduce mortality estimates.
27;44-47
  Thus, we believe that the on-ART mortality 
for our cohort is likely reflective of the true mortality experience of other similar settings.  Of note, an 
overestimate of on-ART mortality would lead to an underestimate of the mortality impact of delays in 
ART initiation.  Programs with lower overall pre-ART and on-ART mortality will not achieve as large an 
absolute reduction in mortality.  Nevertheless, the relative reductions in mortality achievable by 
reducing delays in ART initiation may be similar. 
We also compared our findings to three randomized trials of timing of ART initiation for TB patients.
19-22
  
It is notable that although our overall (pre and on-ART mortality combined) mortality predictions were 
higher than each of the three trials, the absolute increases in mortality were similar when comparing 
similar entry CD4 counts and durations of delay.  The similarity in absolute increases in mortality 
provides added support to the validity of our model.  Our higher overall mortality may reflect the 
differences in routine clinical practice versus clinical trials, especially clinical trials of TB treatment as a 
large proportion of mortality in routine care occurs from undiagnosed and untreated TB.
48
  
The mortality benefit of accelerating ART initiation should be balanced against potential harms.  For 
example, people started on ART sooner may be less likely to be correctly diagnosed with concurrent 
opportunistic illnesses (e.g., TB) or adequately prepared for ART initiation.  This may increase the risk of 
immune reconstitution inflammatory reaction (IRIS) and future non-adherence, respectively.  However, 
IRIS is rarely fatal 
21;22;49
, and limited available evidence suggests that adherence counseling during early 
ART may equal pre-ART counseling.
50
   
As with any model-based analysis, our model has several limitations. First, due to limitations of available 
data, we used primary data with variable duration between CD4 counts to estimate CD4 transition 
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probabilities.  Although this limitation likely introduces the greatest imprecision in our transition 
probabilities, the findings from our uncertainty analyses are reassuring because even a relatively large 
change in the CD4 count transition probability (25% increase or decrease) had a small effect on model 
outcome (Figure 3).  The CD4 transition cohort may show a healthy worker bias with a slower decline in 
CD4 count.  However, a calculated decline of 71 cells/mm
3
/year is consistent with several other studies 
in which CD4 count decline is 34 to 97 cells/mm
3
/year.
51-55
  The pre-ART cohort also may not be 
representative of the natural history of untreated HIV disease, as unmeasured factors may have affected 
delays in ART initiation (e.g., ill-appearing patients started on ART sooner).  However, our analysis is 
designed to reflect the impact of delays in routine care, not in the abstract situation of untreated natural 
history.  Importantly, we may have underestimated the effect of delay by using the date of the first CD4 
test as the date of clinic entry, as delays may occur between clinic entry and CD4 enumeration.  
However, in our clinical setting, CD4 measurement on the first clinic visit was routine, thereby 
minimizing the likely effect of this bias.  Finally, we did not address delays in diagnosis of HIV or entry 
into care following diagnosis because our intent was to focus on delays in ART initiation among patients 
who had already been linked to HIV-specific care.  To provide a full spectrum of the impact of delays on 
HIV-associated morbidity and mortality, future models could also address delays in HIV diagnosis and 
entry-into-care, as well as modeling the impact of such delays on HIV transmission. 
Our findings highlight the need to develop approaches to more promptly initiate ART after patients 
present to care.  These approaches must address both clinic-level and patient-level factors.  Clinic-level 
reduction in delays may be achieved through improved turn-around times in obtaining laboratory 
results, fewer “ART preparation visits”, and streamlined pre-ART assessment protocols.  Interventions 
may include changes in pre-ART counseling, educating staff on the risks of ART delay, and improving 
access to CD4 count testing, including the use of point-of-care CD4 count assays.
28
  Patient-level barriers 
to prompt ART initiation may include barriers to reaching the clinic as well as concerns of ART side 
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effects, stigma, and coping.
9;16;41;56-59
  Proactive patient-centered approaches (e.g., financial enablers, 
community-based educational campaigns, home-based care) to overcome these barriers must be 
advanced if we are to maximize the number of lives saved with ART.  Such programs must also address 
issues of adherence and retention in order to minimize any potential negative consequences of more 
rapid initiation of ART.  Failure to retain patients starting ART would undermine short-term survival 
benefits. 
Our model, based on data from routine programs in South Africa, suggests that the delays in ART 
initiation which are typical of some existing clinics, may cause substantial excess mortality.  Among the 
most immunosuppressed patients, this absolute mortality increase is substantially higher.  Reducing 
delays to ART initiation for all eligible patients in high-burden settings, especially those with lower CD4 
counts and not just those with opportunistic infections, could save thousands of lives every year and 
should be prioritized if the promise of ART in these populations is to be fully realized. 
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FIGURE CAPTIONS: 
Figure 1: Markov state transition model with CD4 states and arrows indicating the allowed transitions 
between states for a cohort followed for 52 weeks from clinic entry and initiating ART at week “k”.  
Mortality occurs from each state each cycle. 
Figure 2: Contour plot of total mortality risk 52 weeks after entering HIV care by duration of delay in ART 
initiation (x-axis) and CD4 at care entry (y-axis).   
CD4 at the time of entry into care is on the y-axis, delay in ART initiation on the x-axis, and contours 
represent mortality bands by percent of the cohort who died 52 weeks after entering care.  The close 
contour lines at lower entry CD4 represent the more rapid increase in mortality with delays among such 
patients. The black line represents the increasing mortality with the whole cohort analysis (median CD4 
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26 
count 143 cells/mm
3
) in which mortality increases from 11.0% with no delay to 19.7% with a 26 week 
delay and 24.2% with a 52 week delay. 
Figure 3:  Tornado diagram of absolute change in percent mortality at 10 weeks and 26 weeks with a 
25% decrease or 25% increase in parameter for CD4 transition, pre-ART mortality, or on-ART mortality.   
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Table 1: Total mortality and excess mortality by delay in ART initiation, stratified by CD4 count at care 
entry 
Total: One year mortality risk (%) according to delay from clinic entry to ART initiation (95% 
uncertainty range) 
Excess: attributable mortality associated with delay (95% uncertainty range) 
CD4, 
cells/mm
3
 
 0 weeks 6 weeks 10 weeks 26 weeks 52 weeks 
State-transition model for pre-ART cohort CD4 distribution 
Total 11.0 (7.2, 15) 13.2 (9.5, 17) 14.7 (11, 18) 19.7 (16, 23) 24.2 (19, 29) Whole Cohort 
(median CD4: 
143) 
Excess 0 2.2 (-3.2, 7.7) 3.7 (-1.8, 9.1) 8.6 (3.4, 14) 13.0 (7.2, 19) 
Total 15.5 (10, 21) 18.8 (13, 24) 20.8 (16, 26) 27.7 (23, 32) 34.2 (28, 40) Restricted to 
CD4 <150 
cell/mm
3
 
Excess 0 3.3 (-4.3, 1.1) 5.2 (-2.2, 13) 12.1 (4.8, 19) 18.6 (10, 27) 
State transition model for pre-ART CD4 strata at entry into clinic 
Total 2.8 (1.7, 3.9) 3.2 (1.9, 4.9) 3.5 (2.0, 6.0) 4.3 (2.1, 8.8) 5.1 (1.5, 12) 
300-350 
Excess 0 0.4 (-1.4, 2.3) 0.7 (-1.6, 3.0) 1.5 (-2.1, 5.2) 2.3 (-3.7, 8.3) 
Total 3.5 (2.2, 4.9) 4.1 (2.6, 6.1) 4.6 (2.7, 7.4) 6.0 (3.2, 11) 7.1 (2.3, 16) 
250-299 
Excess 0 0.6 (-1.4, 2.3) 1.1 (-1.5, 3.8) 2.5 (-1.8, 6.8) 3.6 (-3.2, 10.5) 
Total 4.7 (2.8, 6.6) 5.6 (3.7, 7.6) 6.2 (4.2, 8.7) 8.4 (5.2, 13) 10.0 (5.0, 17) 
200-249 
Excess 0 0.9 (-1.8, 3.6) 1.5 (-1.4, 4.5) 3.7 (-0.7, 8.1) 5.2 (-1.2, 12) 
Total 6.6 (4.1, 9.1) 7.9 (5.3, 10) 8.6 (5.9, 11) 11.6 (8.1, 16) 13.9 (9.0, 21) 
150-199 
Excess 0 1.3 (-2.4, 4.9) 2.0 (-1.8, 5.9) 5.0 (0.37, 10) 7.3 (1.0, 14) 
Total 9.4 (5.5, 14) 11.0 (7.6, 14) 12.2 (8.8, 16) 16.3 (12, 21) 20.0 (14, 27) 
100-149 
Excess 0 1.6 (-3.7, 6.9) 2.8 (-2.6, 8.3) 6.9 (1.0, 13) 10.6 (2.9, 19) 
50-99 Total 13.3 (8.4, 18) 15.6 (10, 21) 17.0 (12, 22) 22.9 (17, 31) 29.2 (21, 40) 
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Excess 0 2.2 (-4.9, 9.3) 3.7 (-3.3, 11) 9.6 (1.1, 18) 15.8 (5.2, 26) 
Total 21.3 (14, 29) 26.2 (19, 33) 29.2 (22, 36) 38.8 (33, 44) 47.4 (39, 55) 
<50 
Excess 0 4.8 (-5.3, 15) 7.8 (-2.1, 18) 17.4 (7.9, 27) 26.1 (15, 37) 
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Table 2: Pre- and on-ART 52 week mortality estimates (per 100-person-years) from the model simulation 
and the published literature 
 CD4 strata (cells/mm
3
) 
Mortality 
per 100 
person-
years 
<25 25-49 50-99 100-
149 
150-
199 
200-
249 
250-
299 
300-
349 
≥350 
Pre-ART          
Model 72 56 34 22 15 11 7.7 7.6 3.8 
Anglaret 69 32 17 4.2 0.6 
Fielding 43 11  3.3 0.6 
Badri 27 8 NR 
Amuron* 80% 50% 31% NR 
On-ART          
Model 29 20 14 9.9 6.9 4.8 3.6 2.8 2.8 
May 24 16 8.7 5.5 5.1 
Brinkhof 17 11 7.3 4.8 3.8 
Mills 13 6.4 4.4 3 3.3 2.2 2.8 
*  mortality risk over a 12month time period; NR not reported 
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Figure 1: Markov state transition model with CD4 states and arrows indicating the allowed transitions 
between states for a cohort followed for 52 weeks from clinic entry and initiating ART at week “k”.  
Mortality occurs from each state each cycle.   
 
Before ART initiation, transitions can occur between adjacent CD4 count states.  After ART initiation, 
mortality is estimated as a function of CD4 count state at ART initiation and weeks since ART initiation, 
and thus there are no transitions between CD4 count states and the boxes are blank because individual 
patients may have a wide range of CD4 counts. 
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Figure 2: Contour plot of total mortality risk 52 weeks after entering HIV care by duration of delay in ART 
initiation (x-axis) and CD4 at care entry (y-axis).   
increasing mortality by delay with median CD4 of 143
50
10
0
15
0
20
0
25
0
30
0
CD
4 
a
t c
a
re
 
e
n
try
 
(ce
lls
/m
m
3)
0 10 20 30 40 50
delay in cART initiation (weeks)
5
10
15
20
25
30
35
40
45
50
%
 
m
or
ta
lity
 
52
 
w
ee
ks
 
af
te
r 
en
te
rin
g 
ca
re
 
CD4 at the time of entry into care is on the y-axis, delay in ART initiation on the x-axis, and contours 
represent mortality bands by percent of the cohort who died 52 weeks after entering care.  The close 
contour lines at lower entry CD4 represent the more rapid increase in mortality with delays among such 
patients. The black line represents the increasing mortality with the whole cohort analysis (median CD4 
count 143 cells/mm
3
) in which mortality increases from 11.0% with no delay to 19.7% with a 26 week 
delay and 24.2% with a 52 week delay. AC
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Figure 3: Tornado diagram of absolute change in percent mortality at 10 weeks and 26 weeks with a 25% 
decrease or 25% increase in parameter for CD4 transition, pre-ART mortality, or on-ART mortality.   
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